Building Sustainable Pharma Growth through Ethical Marketing Practices

In an interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Atul Suri, Senior Vice President & SBU Head, Alembic Pharmaceuticals Limited, discusses how Indian pharma companies strengthen compliance, transparency, and ethical marketing while adopting digital tools and protecting patient data to maintain trust and regulatory alignment. He highlights balancing innovation with accessibility through collaboration and quality to drive sustainable growth in a competitive market.

Atul Suri is a business Transformation Leader with 30+ years of experience, specializing in turnaround strategy, stakeholder management, sales leadership, organizational development, conflict resolution, CXO mentoring, and customer engagement.

With increasing regulatory scrutiny and the push for transparency in pharma marketing, how are companies in India adapting to maintain both compliance and consumer trust?

Today’s market pays to be ethical and highly compliant. While scrutiny on the compliance front has increased, especially with the introduction of UCPMP, most of the top 20 companies operating in the domestic market have already been cognizant of maintaining high ethical standards in their dealings. However, with these guidelines coming into place a few years ago, companies have become even more conscious and are ensuring that their actions remain correct and compliant.

There is no doubt that transparency in pharma marketing is essential. In terms of adaptation, most companies today have well-established compliance teams. Any communication—whether it is directed towards the medical fraternity, such as doctors, or involves medical content, activities, or engagements—is thoroughly reviewed by the compliance team before being released. This ensures that all outputs are aligned with regulatory requirements. Many companies have adopted this approach, and organizations like Alembic Pharmaceuticals have been known for maintaining high ethical standards for over a decade.

The second aspect relates to customer trust. When customers recognize that a company operates ethically and adheres strictly to rules, regulations, and guidelines, trust develops naturally. However, beyond ethical marketing, product quality plays a critical role in reinforcing this trust. It becomes a dual approach—while compliance and transparency in marketing build trust, consistent delivery of high-quality products strengthens and sustains it.

In summary, transparency and compliance are fundamental. Compliance, in particular, leaves little room for ambiguity—it is either adhered to or not. When companies maintain transparency, ensure compliance, and deliver high-quality products, it creates a win-win situation for both the organization and the medical professionals who prescribe their medicines.

Also Read: Enhancing Clinical Trial Supply Chain Resilience to Address Global Disruptions in India

As digital transformation accelerates in the pharmaceutical sector, how are ethical marketing practices evolving in response to the rapid rise of social media and direct-to-consumer advertising in India?

If a company remains highly compliant with marketing practices and follows UCPMP strictly, without any deviations, it will remain ethical—whether promotions are carried out physically or through digital channels. However, social media brings its own dynamics.

It becomes critical for companies to have dedicated teams to monitor not just the communication they release, but also the responses and interpretations it generates. Since social media is open and prone to misinterpretation, companies must ensure that content and reactions do not create confusion or issues for end users, especially patients.

With digital transformation accelerating, companies are increasingly focusing on having specialists who ensure content is compliant before release and continuously monitor audience responses, enabling them to stay in control and maintain ethical standards.

With the heightened focus on data privacy laws and patient consent, how do pharma companies navigate the ethical challenges of leveraging patient data for personalized marketing while ensuring privacy?

Data privacy is of utmost importance, and any violation is unacceptable to regulators, the medical fraternity, and companies alike. Therefore, organizations need to be extremely cautious while handling patient data.

In practice, certain activities in doctors’ chambers may require limited patient data. In such cases, companies must ensure that robust processes are in place. Only relevant data required for analysis or clinical studies should be captured, and this must be approved by the Ethics Committee. There can be no compromise, as the consequences of non-compliance are serious.

A key aspect is training the field force. Since medical representatives are often directly involved in data collection, companies must clearly guide them on what data can and cannot be captured. Standardized forms should be designed to include only permissible fields, minimizing the scope for error.

While data is essential for insights, research, and improving treatment outcomes, companies must strike a balance. They should avoid over-collection of sensitive information and ensure that patient privacy is never compromised. Strong systems and clearly defined processes are critical to making this approach effective and compliant.

Also Read: How Organic Synthesis is Accelerating Drug Discovery in Pharma

In a market increasingly driven by value-based healthcare, how can pharma companies ethically navigate the tension between promoting high-cost therapies and ensuring access to underserved populations in India?

This is a real challenge, especially with high-cost therapies that require significant investment from companies. However, most pharma companies are not solely focused on profits but also on doing what is right for patients and doctors.

One key approach is collaboration with the government to improve access. Addressing the three A’s—affordability, accessibility, and availability—cannot be achieved by companies alone. Partnering with government initiatives and leveraging their wide network can help reach underserved populations more effectively.

Digital tools also play an important role. With widespread access to identity systems like Aadhaar, telemedicine and digital healthcare platforms can help extend care to remote and underserved areas.

Additionally, companies can introduce schemes through CSR initiatives or collaborate with state governments and other organizations to improve access to expensive treatments. Such collective efforts can enhance reach and ensure that even underserved populations benefit from advanced therapies.

How will ethical pharma marketing evolve with AI, telemedicine, and predictive analytics, particularly in ensuring patient autonomy and informed consent?

Technology and digital advancements are clearly transforming how things operate on the ground. Artificial intelligence is better viewed as “assisted intelligence,” supporting doctors and scientists rather than replacing them. In this industry, human judgment remains essential, with technology acting as an enabler.

In terms of ethical pharma marketing, the principle remains unchanged. Whether in physical or digital formats, companies must remain ethical. AI, telemedicine, and predictive analytics only support better decision-making and improved patient-centric outcomes; they do not alter the core requirement of ethical conduct.

Regarding patient autonomy and informed consent, transparency is critical. In any trial or study, all facts must be clearly communicated to both doctors and patients. Only when there is complete clarity and understanding should participation proceed. By maintaining openness, strong processes, and careful implementation, companies can leverage these technologies without compromising ethics.

Also Read: Impact of Modern Technology on the Indian Life Sciences Sector

Looking ahead, how can pharma companies achieve sustainable growth in an increasingly competitive and generic-driven market?

A key addition to this topic is how pharma companies can build sustainable growth through ethical marketing practices, especially in a highly cluttered market.

In today’s scenario, when a molecule goes off patent, multiple brands—sometimes 40 to 60—enter the market almost immediately, as seen recently with GLP-1 semaglutide. In such a competitive environment, differentiation becomes extremely challenging.

In these situations, sustainable growth comes down to two core factors: being genuinely ethical and earning customer trust. When a company consistently follows ethical marketing practices and maintains high compliance standards, it builds credibility among doctors and the medical fraternity. This trust becomes the key driver in brand preference.

For complex therapies, doctors tend to rely on companies known for quality and ethical conduct. Therefore, long-term, sustainable growth is achieved not through aggressive promotion, but through consistent ethical practices and strong product quality.

In essence, it is a simple formula—ethical marketing and customer trust—which ensures steady and sustained growth over time.